Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0601-1
Abstract: SummaryBackground Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory… read more here.
Keywords: combination; afatinib; gemcitabine; afatinib irreversible ... See more keywords
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.12.029
Abstract: BACKGROUND Targeting the epidermal growth factor receptor pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non-small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus… read more here.
Keywords: methodology; afatinib; gem; treatment ... See more keywords
Transformation to small cell lung cancer after first-line afatinib treatment
Sign Up to like & getrecommendations! Published in 2018 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2018.02.011
Abstract: Acquiring resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is inevitable. Transformation to small cell lung cancer (SCLC) is reported as a possible mechanism of this acquired resistance. We describe the case of… read more here.
Keywords: afatinib; transformation; cell lung; transformation small ... See more keywords
Analyses des risques concurrents de progression systémique ou au niveau du système nerveux central chez des patients avec CBNPC EGFR muté ayant reçu de l’afatinib dans les études LUX-Lung 3, 6 et 7
Sign Up to like & getrecommendations! Published in 2019 at "Revue des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2018.10.070
Abstract: Introduction Les metastases au niveau du SNC sont une complication connue du CBNPC avance EGFR mute (m+), et les etudes LUX-Lung (LL) evaluant afatinib autorisaient l’inclusion de patients avec metastases cerebrales (MC). LL3, 6 et 7 ont… read more here.
Keywords: afatinib; progression; snc; chez des ... See more keywords
Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-38676-7
Abstract: Activated epidermal growth factor receptor (EGFR) has been proposed in the pathophysiology of neurodegenerative diseases. In the present study, the anti-inflammatory effect of afatinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKIs) was investigated using CTX-TNA2 cells and… read more here.
Keywords: egfr; afatinib; ogd induced; neuroinflammation ... See more keywords
Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway
Sign Up to like & getrecommendations! Published in 2018 at "Bioscience Reports"
DOI: 10.1042/bsr20181693
Abstract: Acquired resistance of afatinib is a significant challenge for non-small cell lung cancer (NSCLC) therapy and the mechanisms remain unclear. Aberrant activation of epidermal growth factor receptor (EGFR)-dependent downstream pathways, especially phosphatidylinositol-3-kinases/protein kinase B (PI3K/Akt)… read more here.
Keywords: afatinib; akt signaling; pi3k akt; signaling pathway ... See more keywords
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz437.013
Abstract: Abstract Background Afatinib is an irreversible second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) while gefitinib or erlotinib are reversible first-generation EGFR-TKIs. Methods A retrospective analysis of patients with EGFR mutant advanced lung adenocarcinoma… read more here.
Keywords: gefitinib erlotinib; afatinib; first line; gefitinib ... See more keywords
Clinical analysis of EGFR‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13047
Abstract: In the LUX‐Lung 3 and LUX‐Lung 6 trials, afatinib improved overall survival in previously untreated patients with EGFR 19del mutated non‐small cell lung cancer (NSCLC) compared to chemotherapy. The appropriate management of adverse events and… read more here.
Keywords: non small; afatinib; egfr positive; lung cancer ... See more keywords
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Science"
DOI: 10.1111/cas.13571
Abstract: Human epidermal growth factor receptor 2 (HER2) plays an important role in the pathogenesis of various cancers. HER2 alterations have been suggested to be a therapeutic target in non‐small‐cell lung cancer (NSCLC), just as in… read more here.
Keywords: afatinib; resistance; her2 alterations; cancer ... See more keywords
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-061892
Abstract: Introduction Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is read more here.
Keywords: cancer; afatinib; treatment; medicine ... See more keywords
The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Oncology"
DOI: 10.1155/2023/5493725
Abstract: Aim The aim of this study is to evaluate the efficacy and safety of afatinib in the treatment of non-small cell lung cancer (NSCLC) patients with brain metastasis based on meta-analysis. Methods Related literatures were… read more here.
Keywords: afatinib; patients brain; meta analysis; safety afatinib ... See more keywords